OKYO Key Statistics, Chart & Performance
The current stock price of OKYO is 2.355 USD. In the past month the price increased by 2.46%. In the past year, price increased by 98.1%.
OKYO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to OKYO. When comparing the yearly performance of all stocks, OKYO is one of the better performing stocks in the market, outperforming 91.58% of all stocks.
OKYO Financial Highlights
Over the last trailing twelve months OKYO reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 79.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.98% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OKYO Forecast & Estimates
9 analysts have analysed OKYO and the average price target is 8.5 USD. This implies a price increase of 260.93% is expected in the next year compared to the current price of 2.355.
OKYO Ownership
OKYO Latest News, Press Relases and Analysis
About OKYO
Company Profile
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Company Info
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London GB
Employees: 4
Phone: 442074952379
OKYO PHARMA LTD / OKYO FAQ
What does OKYO PHARMA LTD do?
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. The company has completed a Phase II trial in patients with DED and NCP. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
What is the current price of OKYO stock?
The current stock price of OKYO is 2.355 USD. The price increased by 13.22% in the last trading session.
What is the dividend status of OKYO PHARMA LTD?
OKYO does not pay a dividend.
What is the ChartMill rating of OKYO PHARMA LTD stock?
OKYO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for OKYO stock?
OKYO PHARMA LTD (OKYO) currently has 4 employees.
What is the market capitalization of OKYO stock?
OKYO PHARMA LTD (OKYO) has a market capitalization of 51.27M USD. This makes OKYO a Micro Cap stock.
What is the outstanding short interest for OKYO PHARMA LTD?
The outstanding short interest for OKYO PHARMA LTD (OKYO) is 0.39% of its float.